BioNTech SEBNTX +1.36%62 FCF Yield % is 3.11 as of Jun. 28, 2026, which is 65% above its 10-year median of 1.89. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $89.10 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, BioNTech SE ranks better than 90.82% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BioNTech SE FCF Yield % Related Terms
BioNTech SE FCF Yield % Historical Data
* Premium members only.
The historical data trend for BioNTech SE's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioNTech SE's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's FCF Yield % distribution charts can be found below:
* The bar in red indicates where BioNTech SE's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BNTX) has a FCF Yield % of 3.11 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on BioNTech SE and its competitors. This is 65% above median its historical median of 1.89. According to the industry distribution chart, BioNTech SE ranks #130 out of 1416 companies in the Biotechnology industry, placing it in the top 9.2%.
Is BioNTech SE's FCF Yield % too high?
BioNTech SE's current FCF Yield % of 3.11 is 65% above median its 10-year median of 1.89. Based on the distribution chart, BioNTech SE ranks #130 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's FCF Yield % compare to RPRX and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #130 out of 1416 companies for FCF Yield %. This places BioNTech SE in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on BioNTech SE and its competitors. BioNTech SE's current FCF Yield % is 3.11, which is 65% above median its own 10-year median of 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $89.10, compared to a current price of $91.22 — trading 2.4% above its estimated fair value. The current FCF Yield % is 3.11, which is 65% above median its 10-year median of 1.89. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For BioNTech SE (BNTX), the current FCF Yield % is 3.11 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $91.22 is trading 2.4% above its estimated GF Value™ of $89.10.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
FCF Yield %: 3.11 (65% above median its 10-year median of 1.89)
GF Value™: $89.10 vs. price of $91.22 (2.4% above fair value)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
